Group items tagged

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution developed by Danish specialist LEO Pharma. This injectable solution contains 300 mg of tralokinumab in a 2 mL pre-filled pen and will be available for tralokinumab patients in the UK from early 2024. Tralokinumab is indicated for treating moderate-to-severe atopic dermatitis in adult and adolescent patients aged 12 and older who require systemic therapy, Leo Pharma said in a statement. It is a fully human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine. Previously, it was available in a 150 mg in 1 mL pre-filled syringe. According to Leo Pharma, the 300 mg tralokinumab in a 2 mL pre-filled pen offers a streamlined administration for both patients and prescribers. It begins with an initial 600 mg dose in two injections, followed by a single 300 mg maintenance dose administered every other week. "We're pleased that this simplified administration method for tralokinumab will soon benefit eligible atopic dermatitis patients in the UK. It aligns with our commitment to elevate the standard of care and support for individuals with skin conditions," said Leanne Walsh, Vice President and General Manager of UK and Ireland at LEO Pharma.

New Lamotrigine Desitin 10mg/ml Oral Suspension is the first licensed Lamotrigine oral liquid medicine available in the UK, offering simple, accurate and flexible dosing for vulnerable patient groups with epilepsy and bi-polar disorder. Accurate dosing and slow titration are essential when initially prescribing for patients with epilepsy. This helps minimise the risk of potentially life-threatening side effects such as Stevens-Johnson syndrome (an acute, rare, and occasionally fatal skin reaction). Dose escalation is required every 2 weeks until the optimal dose is achieved to reach the desired maintenance level. Lamotrigine Desitin 10mg/ml Oral Suspension helps simplify complex prescribing and dispensing regimes, as all dosing requirements are covered in a single product. The supplied dosing syringe and cup make it simple for patients to use and carers to administer. The licensed Oral Suspension is likely to be of benefit when prescribing for children (over 2 years), older people (particularly patients with dysphagia) and also those with learning disabilities. The 10mg/ml strength simplifies accurate dosing for children and offers complete flexibility when dosing is based on mg/kg body weight.

Obat tahan lama ml >> Anda kurang bergairah di ranjang ,dan tidak mendapatkan kebahagiaan anda dalam masalah sek anda jangan khawatir lagi karena kami selaku pusat obat kuat indonesia terbesar akan memberikan solusi anda dengan mengunakan Obat tahan lama ml trica jus yang akan membantu anda , karena trica jus

Insuman Comb 50 100units/ml suspension for injection 3ml cartridges has been discontinued with stocks being exhausted imminently, notified Department of Health and Social Care (DHSC). The department has issued a medicine supply notification for Insulin isophane biphasic human 50/50 (Insuman Comb 50) 100units/ml suspension for injection 3ml cartridge. "Humolog Mix 50 remains available, as do other biphasic insulin preparations, and the manufacturers can support a full uplift in supply," said DHSC. A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses. DHSC and NHSE/I's newly launched online Medicines Supply Tool provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

Refurbished Abbott Hospira Plum A+ 3 Infusion Pump. The A+3 is a triple channel pump that allows each channel to be programmed and ran individually. Delivery rates in include primary, secondary and concurrent. The A+3 allows for a variety of delivery units including: mL/hr, mcg/kg/min, mcg/min, mcg/kg/hr, cg/hr, mg/min, mg/kg/hr, mg/hr, ng/kg/min, g/hr, mEq/hr, Million units/hr, units/min, units/hr, units/kg/hr, units/kg/min, mmol/min, mmol/hr. *Refurbished *1-Year Warranty

Refurbished Abbott Hospira Plum A+ 3 Infusion Pump. The A+3 is a triple channel pump that allows each channel to be programmed and ran individually. Delivery rates in include primary, secondary and concurrent. The A+3 allows for a variety of delivery units including: mL/hr, mcg/kg/min, mcg/min, mcg/kg/hr, cg/hr, mg/min, mg/kg/hr, mg/hr, ng/kg/min, g/hr, mEq/hr, Million units/hr, units/min, units/hr, units/kg/hr, units/kg/min, mmol/min, mmol/hr. *Refurbished *1-Year Warranty

Refurbished Abbott Hospira Plum A+ 3 Infusion Pump. The A+3 is a triple channel pump that allows each channel to be programmed and ran individually. Delivery rates in include primary, secondary and concurrent. The A+3 allows for a variety of delivery units including: mL/hr, mcg/kg/min, mcg/min, mcg/kg/hr, cg/hr, mg/min, mg/kg/hr, mg/hr, ng/kg/min, g/hr, mEq/hr, Million units/hr, units/min, units/hr, units/kg/hr, units/kg/min, mmol/min, mmol/hr. *Refurbished *1-Year Warranty

heo tiến sĩ, bác sĩ Nguyễn Bách, Khoa Nội thận Lọc máu Bệnh viện Thống nhất TP HCM cho biết, bình thương, một người khỏe mạnh đi tiểu khoảng 8 lần trong ngày, trong đó có 7 lần vào ban ngày và một lần vào ban đêm. Lượng nước tiểu mỗi lần là khoảng 300 ml. Nếu bạn đi tiểu nhiều hơn một lần vào ban đêm thì được gọi là tiểu đêm.

Faster, stronger and more effective, Quicksilver Scientific's liposomal delivery of nanoemulsified Colorado Hemp Oil far outpaces tinctures.

The Medicines and Healthcare products Regulatory Agency has issued a class 2 medicines recall notice for Olopatadine USV 1mg/ml eye drops. Specific batches of this product are being recalled by USV UK Limited as a precautionary measure due to the identification of out of specification results for impurities during routine stability testing. USV UK Limited are recalling the affected batches as a precautionary measure due to out of specification results for impurities during routine stability testing.

The Medicines & Healthcare products Regulatory Agency has initiated a recall of three batches of Quantum Pharmaceutical's Diltiazem HCl 2% Cream, which is an unlicensed medicine. MHRA issued a precautionary recall of the cream due to a change in the product's appearance that affected its thickness. Pharmacists are instructed to halt supply, quarantine remaining stock, and contact Quantum Pharmaceutical to return affected batches M1402497, M1402574, and M1402680. Patients using this product may encounter application issues with the cream due to its consistency. However, MHRA said that this has not impacted the product's effectiveness or posed any risk to patient safety. The MHRA also reported that medac GmbH (t/a medac Pharma LLP) is conducting a recall of two batches of Sodiofolin 50 mg/ml solution for injection/infusion (400mg/8ml vial) with batch numbers G220393B and G220393C. This class 2 medicines recall is a result of particles detected during long-term stability tests.

Silver Diamine Fluoride 38% Caries Protecting Solution Caries Remover fagmin COMPOSITION : Silver diamine fluoride contains approximately 24-28 % (weight/volume) silver and 5-6 % (weight/volume) Research on the use of Silver Diamine Fluoride says exposure to one drop of SDF orally would result in less fluoride ion content than is present in a 0.25 mL topical treatment of fluoride varnish. The exact amount of silver and fluoride present in one drop of SDF is determined by the specific gravity of the liquid and the dropper used. The main disadvantage of SDF is its esthetic result (i.e., permanently blackens enamel and dentinal caries lesions and creates a temporary henna-appearing tattoo if allowed to come in contact with skin). Skin pigmentation is temporary since the silver does not penetrate the dermis Practical Applications in the following cases : High caries-risk patients with anterior or posterior active cavitated lesions havioral or medical management challenges Patients with multiple cavitated caries lesions that may not all be treated in one visit Difficult to treat cavitated dental caries lesions Patients without access to or with difficulty accessing dental care Active cavitated caries lesions with no clinical signs of pulp involvement.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on Wednesday (14 June). It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg tablets are out of stock until mid-July 2023. However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand. "Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC. "Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."

Size - 100 ml Long-Lasting Fragrance Strong & Refreshing Scent be it Parties, Meetings or Hangouts.

Colonis, a subsidiary company of the Clinigen Group has received the Medicines and Healthcare products Regulatory Agency (MHRA) approval for Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD). Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25%-50%. Sleep onset insomnia in children with ADHD can affect their mood, attention, behaviour and school performance. Henno Welgemoed, Director of Medical Affairs at Colonis said: "We welcome the MHRA's approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks."

Kent Pharma UK has announced a precautionary recall of multiple batches of Itraconazole 10mg/ml oral solution following the identification of out-of-specification appearance in the solution, particularly the presence of suspended particles or clusters of crystals. Itraconazole is an antifungal medication prescribed for treating fungal or yeast infections in different parts of the body. Its oral solution form is specifically intended for treating oropharyngeal or esophageal candidiasis, commonly known as thrush or oral thrush. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised the recall following initial investigations, which indicated a solubilisation issue of the active ingredient, itraconazole. This problem may result in some doses containing lower amounts of the active ingredient. The root cause of the issue is currently under investigation. However, due to the potential for underdosage, the affected batches are being recalled as a precautionary measure.

Victoza (liraglutide) 6mg/mL pre-filled injection pens, previously used in the treatment of type 2 diabetes mellitus (T2DM), have been out of stock in the UK since August 2023. Novo Nordisk has confirmed to The Pharmaceutical Journal that the product has now been discontinued as part of their broader strategy to consolidate their portfolio. The Danish pharmaceutical company said that they are in close dialogue with the Department of Health and Social Care (DHSC), which is expected to release guidance outlining timelines, alternative treatments, and recommended next steps for healthcare professionals. However, the company clarified that they have no plans to discontinue Saxenda (liraglutide) pre-filled injection pens, though this product has also faced supply restrictions in the UK since shortages began. The DHSC initially announced a national shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including Victoza, in June 2023. At that time, prescribers were advised to limit use of these drugs for their licensed indications and to avoid initiating new GLP-1 RA therapies for T2DM patients during the shortage.